Literature DB >> 21574186

Risk of surgical delivery to deep nuclei: a meta-analysis.

Jonathan Kimmelman1, Katherine Duckworth, Tim Ramsay, Tiffini Voss, Bernard Ravina, Marina Elena Emborg.   

Abstract

Many novel strategies aimed at neuroprotection or neurorestoration involve surgical delivery of agents to deep nuclei along multiple trajectories. Using intracerebral hemorrhage on a per-trajectory basis as our primary end point, we quantified the level of surgical risk associated with agent delivery to deep nuclei. Secondarily, we quantified other event rates and examined relationships between intracerebral hemorrhage and 8 variables related to patient and practice characteristics. Meta-analytic techniques were used to pool complication rates reported in published articles involving deep brain stimulator electrode implantation or infusion of vectors, tissues, or trophic factors. One hundred nine studies were included in our analysis, comprising 6237 patients and 9890 trajectories to deep nuclei. The estimated per-trajectory intracerebral hemorrhage rate was 1.57% (95% confidence interval, 1.26%-1.95%). The proportion of trajectories leading to permanent or serious neurological deficits was 0.41% (0.28%-0.60%). The estimated mortality rate per trajectory was 0.14% (0.07%-0.29%). No relationship between intracerebral hemorrhage and sex, age, duration of disease, or exclusion of patients with surgical complications was observed; a significant positive relationship was observed with the use of microelectrode recording and a significant negative relationship with putamenal delivery. Our results show a significant difference in intracerebral hemorrhage rates between inoculations and electrode implantation. Our findings suggest that studies involving multiple trajectories to deep nuclei involve a high level of risk. However, inoculations may be significantly safer than electrode implantation. Our analysis has implications for the ethics of preclinical research, independent review of risk, subject selection, and adverse event reporting.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Year:  2011        PMID: 21574186      PMCID: PMC4532377          DOI: 10.1002/mds.23770

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  17 in total

1.  Extending clinical equipoise to phase 1 trials involving patients: unresolved problems.

Authors:  James A Anderson; Jonathan Kimmelman
Journal:  Kennedy Inst Ethics J       Date:  2010-03

Review 2.  Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes.

Authors:  Galit Kleiner-Fisman; Jan Herzog; David N Fisman; Filippo Tamma; Kelly E Lyons; Rajesh Pahwa; Anthony E Lang; Günther Deuschl
Journal:  Mov Disord       Date:  2006-06       Impact factor: 10.338

3.  Psychiatric and neuropsychiatric adverse events associated with deep brain stimulation: A meta-analysis of ten years' experience.

Authors:  Brian S Appleby; Patrick S Duggan; Alan Regenberg; Peter V Rabins
Journal:  Mov Disord       Date:  2007-09-15       Impact factor: 10.338

4.  Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.

Authors:  Thomas G Roberts; Bernardo H Goulart; Lee Squitieri; Sarah C Stallings; Elkan F Halpern; Bruce A Chabner; G Scott Gazelle; Stan N Finkelstein; Jeffrey W Clark
Journal:  JAMA       Date:  2004-11-03       Impact factor: 56.272

5.  A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease.

Authors:  Mark H Tuszynski; Leon Thal; Mary Pay; David P Salmon; Hoi Sang U; Roy Bakay; Piyush Patel; Armin Blesch; H Lee Vahlsing; Gilbert Ho; Gang Tong; Steven G Potkin; James Fallon; Lawrence Hansen; Elliott J Mufson; Jeffrey H Kordower; Christine Gall; James Conner
Journal:  Nat Med       Date:  2005-04-24       Impact factor: 53.440

6.  Risks and benefits of phase 1 oncology trials, 1991 through 2002.

Authors:  Elizabeth Horstmann; Mary S McCabe; Louise Grochow; Seiichiro Yamamoto; Larry Rubinstein; Troy Budd; Dale Shoemaker; Ezekiel J Emanuel; Christine Grady
Journal:  N Engl J Med       Date:  2005-03-03       Impact factor: 91.245

7.  Deep brain stimulation for Parkinson's disease: prevalence of adverse events and need for standardized reporting.

Authors:  Aleksandar Videnovic; Leo Verhagen Metman
Journal:  Mov Disord       Date:  2008-02-15       Impact factor: 10.338

8.  Deep brain stimulation for Parkinson's disease: the Vanderbilt University Medical Center experience, 1998-2004.

Authors:  Chandler E Gill; Peter E Konrad; Thomas L Davis; David Charles
Journal:  Tenn Med       Date:  2007-04

9.  Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.

Authors:  Michael G Kaplitt; Andrew Feigin; Chengke Tang; Helen L Fitzsimons; Paul Mattis; Patricia A Lawlor; Ross J Bland; Deborah Young; Kristin Strybing; David Eidelberg; Matthew J During
Journal:  Lancet       Date:  2007-06-23       Impact factor: 79.321

10.  Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty.

Authors:  Jonathan Kimmelman; Alex John London
Journal:  PLoS Med       Date:  2011-03-08       Impact factor: 11.069

View more
  13 in total

Review 1.  Ethical development of stem-cell-based interventions.

Authors:  Amanda MacPherson; Jonathan Kimmelman
Journal:  Nat Med       Date:  2019-07-03       Impact factor: 53.440

2.  [Deep brain stimulation for Parkinson's disease: timing and patient selection].

Authors:  R Erasmi; G Deuschl; K Witt
Journal:  Nervenarzt       Date:  2014-02       Impact factor: 1.214

3.  Deep brain stimulation for the treatment of Parkinson's disease: efficacy and safety.

Authors:  Nader Pouratian; Sandeep Thakkar; Won Kim; Jeff M Bronstein
Journal:  Degener Neurol Neuromuscul Dis       Date:  2012-09-04

4.  Pathways of infusate loss during convection-enhanced delivery into the putamen nucleus.

Authors:  Martin L Brady; Raghu Raghavan; Andrew Alexander; Ken Kubota; Karl Sillay; Marina E Emborg
Journal:  Stereotact Funct Neurosurg       Date:  2013-01-22       Impact factor: 1.875

5.  Titer and product affect the distribution of gene expression after intraputaminal convection-enhanced delivery.

Authors:  Marina E Emborg; Samuel A Hurley; Valerie Joers; Do P M Tromp; Christine R Swanson; Sachiko Ohshima-Hosoyama; Viktorya Bondarenko; Kyle Cummisford; Marc Sonnemans; Stephan Hermening; Bas Blits; Andrew L Alexander
Journal:  Stereotact Funct Neurosurg       Date:  2014-06-12       Impact factor: 1.875

Review 6.  Etiologies of intracerebral hematomas.

Authors:  Qingliang T Wang; Stanley Tuhrim
Journal:  Curr Atheroscler Rep       Date:  2012-08       Impact factor: 5.113

Review 7.  A theoretical framework for early human studies: uncertainty, intervention ensembles, and boundaries.

Authors:  Jonathan Kimmelman
Journal:  Trials       Date:  2012-09-22       Impact factor: 2.279

8.  Differential effects of two MRI contrast agents on the integrity and distribution of rAAV2 and rAAV5 in the rat striatum.

Authors:  Sue Osting; Antonette Bennett; Shelby Power; Jordan Wackett; Samuel A Hurley; Andrew L Alexander; Mavis Agbandje-Mckena; Corinna Burger
Journal:  Mol Ther Methods Clin Dev       Date:  2014-01-08       Impact factor: 6.698

9.  Better to be in The Placebo Arm for Trials of Neurological Therapies?

Authors:  Jonathan Kimmelman
Journal:  Cell Transplant       Date:  2018-06-01       Impact factor: 4.064

10.  White Matter Changes Along the Electrode Lead in Patients Treated With Deep Brain Stimulation.

Authors:  Richard Erasmi; Oliver Granert; Dmitry Zorenkov; Daniela Falk; Fritz Wodarg; Günther Deuschl; Karsten Witt
Journal:  Front Neurol       Date:  2018-11-21       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.